{"id":12823,"date":"2026-10-29T09:50:42","date_gmt":"2026-10-29T08:50:42","guid":{"rendered":"https:\/\/www.iqac.csic.es\/?post_type=proyecto&#038;p=12823"},"modified":"2026-10-30T10:03:35","modified_gmt":"2026-10-30T09:03:35","slug":"desenvolupament-de-la-neuritina-1-com-a-candidat-terapeutic-per-a-lobesitat-i-la-malaltia-hepatica-metabolica","status":"publish","type":"proyecto","link":"https:\/\/www.iqac.csic.es\/ca\/projecte\/desenvolupament-de-la-neuritina-1-com-a-candidat-terapeutic-per-a-lobesitat-i-la-malaltia-hepatica-metabolica\/","title":{"rendered":"Desenvolupament de la Neuritina 1 com a candidat terap\u00e8utic per a l&#8217;obesitat i la malaltia hep\u00e0tica metab\u00f2lica"},"content":{"rendered":"<p>L&#8217;obesitat i les malalties associades constitueixen una crisi sanit\u00e0ria important i estan vinculades al risc cardiovascular. Aquesta investigaci\u00f3 se centra en una prote\u00efna anomenada Neuritin 1 (NRN1), que regula el metabolisme del greix marr\u00f3. El greix marr\u00f3 crema calories, fet que augmenta la despesa energ\u00e8tica i redueix el greix corporal. Els nostres estudis inicials han revelat que la NRN1 redueix el greix en ratolins sotmesos a una dieta rica en greixos, la qual cosa demostra el seu potencial com a f\u00e0rmac.<\/p>\n<p>El projecte NEURIMET t\u00e9 com a objectiu esbrinar, en humans, el mecanisme d&#8217;acci\u00f3 exacte de la NRN1. Es preveu desenvolupar una variant millorada de la NRN1 per convertir-la en un tractament efica\u00e7 per als trastorns metab\u00f2lics humans.<\/p>\n<p>El projecte NEURIMET est\u00e0 finan\u00e7at per la Fundaci\u00f3 La Caixa i el duen a terme els grups de Juan B. Blanco (IQAC), Jos\u00e9 M. Fern\u00e1ndez Real (IDIBGI) i Antonio Zorzano (IRB Barcelona, \u200b\u200bgrup coordinador).<\/p>\n<p><img decoding=\"async\" class=\"alignnone size-medium wp-image-12829\" src=\"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/10\/Logo_horizontal_CMYK_english-300x92.jpg\" alt=\"\" width=\"300\" height=\"92\" srcset=\"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/10\/Logo_horizontal_CMYK_english-300x92.jpg 300w, https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/10\/Logo_horizontal_CMYK_english-1024x316.jpg 1024w, https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/10\/Logo_horizontal_CMYK_english-768x237.jpg 768w, https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/10\/Logo_horizontal_CMYK_english-1536x473.jpg 1536w, https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/10\/Logo_horizontal_CMYK_english-1568x483.jpg 1568w, https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/10\/Logo_horizontal_CMYK_english.jpg 1713w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La Neuritina 1, una prote\u00efna present al teixit adip\u00f3s marr\u00f3, t\u00e9 potencial cl\u00ednic per al tractament de l&#8217;obesitat i les malalties metab\u00f2liques. Aquest projecte permetr\u00e0 obtenir an\u00e0legs de la Neuritina 1 amb propietats farmacol\u00f2giques millorades.<\/p>\n","protected":false},"featured_media":12824,"parent":0,"template":"","meta":{"_acf_changed":false},"tags":[140,134],"enfermedad":[125],"framework":[133],"linea-de-investigacion":[115,117],"class_list":["post-12823","proyecto","type-proyecto","status-publish","has-post-thumbnail","hentry","tag-proteinas","tag-quimica-medica-2","enfermedad-cardiovascular","framework-fundacio-la-caixa","linea-de-investigacion-prevenir","linea-de-investigacion-tratar","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Desenvolupament de la Neuritina 1 com a candidat terap\u00e8utic per a l&#039;obesitat i la malaltia hep\u00e0tica metab\u00f2lica | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.iqac.csic.es\/ca\/projecte\/desenvolupament-de-la-neuritina-1-com-a-candidat-terapeutic-per-a-lobesitat-i-la-malaltia-hepatica-metabolica\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Desenvolupament de la Neuritina 1 com a candidat terap\u00e8utic per a l&#039;obesitat i la malaltia hep\u00e0tica metab\u00f2lica | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\" \/>\n<meta property=\"og:description\" content=\"La Neuritina 1, una prote\u00efna present al teixit adip\u00f3s marr\u00f3, t\u00e9 potencial cl\u00ednic per al tractament de l&#039;obesitat i les malalties metab\u00f2liques. Aquest projecte permetr\u00e0 obtenir an\u00e0legs de la Neuritina 1 amb propietats farmacol\u00f2giques millorades.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.iqac.csic.es\/ca\/projecte\/desenvolupament-de-la-neuritina-1-com-a-candidat-terapeutic-per-a-lobesitat-i-la-malaltia-hepatica-metabolica\/\" \/>\n<meta property=\"og:site_name\" content=\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/iqac.csic.es\/\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-30T09:03:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/10\/LaCaixa_JuanBautistaBlanco.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"753\" \/>\n\t<meta property=\"og:image:height\" content=\"564\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@IQAC_CSIC\" \/>\n<meta name=\"twitter:label1\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/projecte\\\/desenvolupament-de-la-neuritina-1-com-a-candidat-terapeutic-per-a-lobesitat-i-la-malaltia-hepatica-metabolica\\\/\",\"url\":\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/projecte\\\/desenvolupament-de-la-neuritina-1-com-a-candidat-terapeutic-per-a-lobesitat-i-la-malaltia-hepatica-metabolica\\\/\",\"name\":\"Desenvolupament de la Neuritina 1 com a candidat terap\u00e8utic per a l'obesitat i la malaltia hep\u00e0tica metab\u00f2lica | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/projecte\\\/desenvolupament-de-la-neuritina-1-com-a-candidat-terapeutic-per-a-lobesitat-i-la-malaltia-hepatica-metabolica\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/projecte\\\/desenvolupament-de-la-neuritina-1-com-a-candidat-terapeutic-per-a-lobesitat-i-la-malaltia-hepatica-metabolica\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/LaCaixa_JuanBautistaBlanco.jpg\",\"datePublished\":\"2026-10-29T08:50:42+00:00\",\"dateModified\":\"2026-10-30T09:03:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/projecte\\\/desenvolupament-de-la-neuritina-1-com-a-candidat-terapeutic-per-a-lobesitat-i-la-malaltia-hepatica-metabolica\\\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/projecte\\\/desenvolupament-de-la-neuritina-1-com-a-candidat-terapeutic-per-a-lobesitat-i-la-malaltia-hepatica-metabolica\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/projecte\\\/desenvolupament-de-la-neuritina-1-com-a-candidat-terapeutic-per-a-lobesitat-i-la-malaltia-hepatica-metabolica\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/LaCaixa_JuanBautistaBlanco.jpg\",\"contentUrl\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/LaCaixa_JuanBautistaBlanco.jpg\",\"width\":753,\"height\":564},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/projecte\\\/desenvolupament-de-la-neuritina-1-com-a-candidat-terapeutic-per-a-lobesitat-i-la-malaltia-hepatica-metabolica\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/www.iqac.csic.es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Desenvolupament de la Neuritina 1 com a candidat terap\u00e8utic per a l&#8217;obesitat i la malaltia hep\u00e0tica metab\u00f2lica\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#website\",\"url\":\"https:\\\/\\\/www.iqac.csic.es\\\/\",\"name\":\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\",\"description\":\"Chemistry for a better life\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#organization\"},\"alternateName\":\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.iqac.csic.es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#organization\",\"name\":\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\",\"alternateName\":\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\",\"url\":\"https:\\\/\\\/www.iqac.csic.es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/cropped-favicon-1.png\",\"contentUrl\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/cropped-favicon-1.png\",\"width\":512,\"height\":512,\"caption\":\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\"},\"image\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/iqac.csic.es\\\/\",\"https:\\\/\\\/x.com\\\/IQAC_CSIC\",\"https:\\\/\\\/www.instagram.com\\\/iqac_csic\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UC1JXTOe3-s8UnYu_A6-SI3A\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/iqac-csic\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Desenvolupament de la Neuritina 1 com a candidat terap\u00e8utic per a l'obesitat i la malaltia hep\u00e0tica metab\u00f2lica | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.iqac.csic.es\/ca\/projecte\/desenvolupament-de-la-neuritina-1-com-a-candidat-terapeutic-per-a-lobesitat-i-la-malaltia-hepatica-metabolica\/","og_locale":"ca_ES","og_type":"article","og_title":"Desenvolupament de la Neuritina 1 com a candidat terap\u00e8utic per a l'obesitat i la malaltia hep\u00e0tica metab\u00f2lica | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","og_description":"La Neuritina 1, una prote\u00efna present al teixit adip\u00f3s marr\u00f3, t\u00e9 potencial cl\u00ednic per al tractament de l'obesitat i les malalties metab\u00f2liques. Aquest projecte permetr\u00e0 obtenir an\u00e0legs de la Neuritina 1 amb propietats farmacol\u00f2giques millorades.","og_url":"https:\/\/www.iqac.csic.es\/ca\/projecte\/desenvolupament-de-la-neuritina-1-com-a-candidat-terapeutic-per-a-lobesitat-i-la-malaltia-hepatica-metabolica\/","og_site_name":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","article_publisher":"https:\/\/www.facebook.com\/iqac.csic.es\/","article_modified_time":"2026-10-30T09:03:35+00:00","og_image":[{"width":753,"height":564,"url":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/10\/LaCaixa_JuanBautistaBlanco.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@IQAC_CSIC","twitter_misc":{"Temps estimat de lectura":"2 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.iqac.csic.es\/ca\/projecte\/desenvolupament-de-la-neuritina-1-com-a-candidat-terapeutic-per-a-lobesitat-i-la-malaltia-hepatica-metabolica\/","url":"https:\/\/www.iqac.csic.es\/ca\/projecte\/desenvolupament-de-la-neuritina-1-com-a-candidat-terapeutic-per-a-lobesitat-i-la-malaltia-hepatica-metabolica\/","name":"Desenvolupament de la Neuritina 1 com a candidat terap\u00e8utic per a l'obesitat i la malaltia hep\u00e0tica metab\u00f2lica | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","isPartOf":{"@id":"https:\/\/www.iqac.csic.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.iqac.csic.es\/ca\/projecte\/desenvolupament-de-la-neuritina-1-com-a-candidat-terapeutic-per-a-lobesitat-i-la-malaltia-hepatica-metabolica\/#primaryimage"},"image":{"@id":"https:\/\/www.iqac.csic.es\/ca\/projecte\/desenvolupament-de-la-neuritina-1-com-a-candidat-terapeutic-per-a-lobesitat-i-la-malaltia-hepatica-metabolica\/#primaryimage"},"thumbnailUrl":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/10\/LaCaixa_JuanBautistaBlanco.jpg","datePublished":"2026-10-29T08:50:42+00:00","dateModified":"2026-10-30T09:03:35+00:00","breadcrumb":{"@id":"https:\/\/www.iqac.csic.es\/ca\/projecte\/desenvolupament-de-la-neuritina-1-com-a-candidat-terapeutic-per-a-lobesitat-i-la-malaltia-hepatica-metabolica\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.iqac.csic.es\/ca\/projecte\/desenvolupament-de-la-neuritina-1-com-a-candidat-terapeutic-per-a-lobesitat-i-la-malaltia-hepatica-metabolica\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.iqac.csic.es\/ca\/projecte\/desenvolupament-de-la-neuritina-1-com-a-candidat-terapeutic-per-a-lobesitat-i-la-malaltia-hepatica-metabolica\/#primaryimage","url":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/10\/LaCaixa_JuanBautistaBlanco.jpg","contentUrl":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/10\/LaCaixa_JuanBautistaBlanco.jpg","width":753,"height":564},{"@type":"BreadcrumbList","@id":"https:\/\/www.iqac.csic.es\/ca\/projecte\/desenvolupament-de-la-neuritina-1-com-a-candidat-terapeutic-per-a-lobesitat-i-la-malaltia-hepatica-metabolica\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/www.iqac.csic.es\/"},{"@type":"ListItem","position":2,"name":"Desenvolupament de la Neuritina 1 com a candidat terap\u00e8utic per a l&#8217;obesitat i la malaltia hep\u00e0tica metab\u00f2lica"}]},{"@type":"WebSite","@id":"https:\/\/www.iqac.csic.es\/#website","url":"https:\/\/www.iqac.csic.es\/","name":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","description":"Chemistry for a better life","publisher":{"@id":"https:\/\/www.iqac.csic.es\/#organization"},"alternateName":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.iqac.csic.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.iqac.csic.es\/#organization","name":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","alternateName":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","url":"https:\/\/www.iqac.csic.es\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.iqac.csic.es\/#\/schema\/logo\/image\/","url":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2025\/11\/cropped-favicon-1.png","contentUrl":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2025\/11\/cropped-favicon-1.png","width":512,"height":512,"caption":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC"},"image":{"@id":"https:\/\/www.iqac.csic.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/iqac.csic.es\/","https:\/\/x.com\/IQAC_CSIC","https:\/\/www.instagram.com\/iqac_csic","https:\/\/www.youtube.com\/channel\/UC1JXTOe3-s8UnYu_A6-SI3A","https:\/\/www.linkedin.com\/company\/iqac-csic\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/proyecto\/12823","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/proyecto"}],"about":[{"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/types\/proyecto"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/media\/12824"}],"wp:attachment":[{"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/media?parent=12823"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/tags?post=12823"},{"taxonomy":"enfermedad","embeddable":true,"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/enfermedad?post=12823"},{"taxonomy":"framework","embeddable":true,"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/framework?post=12823"},{"taxonomy":"linea-de-investigacion","embeddable":true,"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/linea-de-investigacion?post=12823"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}